This report is no longer available. Click here to view our current reports or contact us to discuss a custom report.
If you have previously purchased this report then please use the download links on the right to download the files.
1. | EXECUTIVE SUMMARY |
1.1. | Overview |
1.2. | What is Tissue Engineering? |
1.3. | How are Tissues Engineered? |
1.4. | Key Players |
1.5. | Key Drivers |
1.6. | Key Opportunities |
1.7. | Tissue Engineered Products Market Forecast 2018 - 2028 |
1.8. | Tissue Engineered Products for Clinical Use Market Forecast 2018 - 2028 |
1.9. | Tissue Engineered Products for Research Use Market Forecast 2018 - 2028 |
1.10. | Key Technologies |
1.11. | Key Challenges |
2. | INTRODUCTION |
2.1. | Report Scope |
2.2. | Advantages of 3D Cell Culture |
2.3. | Key Driver: Regenerative Medicine |
2.4. | Key Driver: Unmet Need in Organs for Transplant |
2.5. | Key Driver: Product Testing in Medicine |
2.6. | Key Driver: Avoiding Costly Drug Trial Failures |
2.7. | Key Driver: Product Testing in Consumer Products |
2.8. | Current Challenges: Biological |
2.9. | Current Challenges: Commercialization |
2.10. | Tissue Engineering in 2017 |
3. | KEY OPPORTUNITIES |
3.1. | Overview |
3.2. | Testing of Cosmetics and Other Consumer Goods |
3.3. | Product Testing: Companies |
3.4. | Product Testing: |
3.5. | Drug Screening: Dermagenist |
3.6. | Drug Screening: Drug Development Process |
3.7. | Drug Screening: Benefits of Tissue Engineering |
3.8. | Drug Screening: Cancer |
3.9. | Drug Screening: Organ-on-a-chip |
3.10. | Drug Screening: Companies |
3.11. | Personalised Medicine |
3.12. | Cell-Based Biosensors |
3.13. | Food and Other Animal Products |
3.14. | Esthetics |
4. | TISSUE ENGINEERING CLINICAL LANDSCAPE |
4.1. | Overview |
4.2. | Regenerative Medicine |
4.3. | Competing Products |
4.4. | Competing Products: Advantages and Disadvantages |
4.5. | Commercial Activity |
4.6. | The US Market |
4.7. | Products with FDA Marketing Approval |
4.8. | The European Market |
4.9. | Clinical Trials |
4.10. | Clinical Trials: By Indication and Phase |
4.11. | Skin: Clinical Products |
4.12. | Cartilage: Clinical Products |
4.13. | Cartilage: NeoCart |
4.14. | Pre-Clinical Products |
4.15. | Regulatory Exemptions |
4.16. | Hospital Exemption Scheme |
4.17. | Hospital Exemption Scheme: Problems |
4.18. | 21st Century Cures Act and the Regenerative Medicine Advanced Therapy Designation |
4.19. | Orphan Drug Designation |
4.20. | Scams and Unauthorized Treatments |
4.21. | Moving to Conditional Approval |
4.22. | Moving to Conditional Approval: Case Study |
4.23. | Learning from Medical Innovations |
4.24. | Future |
5. | MARKETS AND FORECASTS |
5.1. | Overview |
5.2. | Market Barriers |
5.3. | Tissue Engineering Value Chain |
5.4. | Tissue Engineering Value Chain: Discussion |
5.5. | Forecasts |
5.6. | Tissue Engineered Products Market Forecast 2018 - 2028 |
5.7. | Companies with Marketed Clinical Products |
5.8. | Companies Developing Engineered Tissues for Clinical Use |
5.9. | Business Models: Engineered Autologous Tissues |
5.10. | Business Models: Cryopreserved Allogeneic Tissues |
5.11. | Tissue Engineered Products for Clinical Use Market Forecast 2018 - 2028 |
5.12. | Companies Engineering Tissues for Research Use |
5.13. | Business Models: Tissues for Research Use |
5.14. | Tissue Engineered Products for Research Use Market Forecast 2018 - 2028 |
5.15. | Companies Producing Organ-On-A-Chips |
5.16. | Companies Producing Lab-Grown Meat |
5.17. | Scaffold Manufacturers |
5.18. | 3D Bioprinter Market and Forecasts |
5.19. | Growing 3D Bioprinting Market |
5.20. | 3D Bioprinting Value Chain |
5.21. | 3D Bioprinting Value Chain: Discussion |
5.22. | 3D Bioprinters by Cost and Technology |
5.23. | 3D Bioprinter Market Forecast 2018 - 2028 |
5.24. | Caveats |
6. | TISSUE ENGINEERING TECHNOLOGIES |
6.1. | Overview |
7. | ESTABLISHED TECHNOLOGIES |
7.1. | Introduction |
7.2. | Semi-Permeable Membranes |
7.3. | Key Semi-Permeable Membrane Manufacturers |
7.4. | Hydrogels |
7.5. | Cell-Laden Hydrogels |
7.6. | Cell-Laden Hydrogels: Companies |
7.7. | Cell-Laden Hydrogels: SWOT Analysis |
8. | 3D BIOPRINTING |
8.1. | Introduction |
8.2. | 3D Bioprinting Process |
8.3. | Comparison of Key Specifications |
8.4. | 3D Bioprinting Technology Comparison |
8.5. | Inkjet: Thermal |
8.6. | Inkjet: Piezoelectric |
8.7. | Inkjet: Companies |
8.8. | Inkjet: SWOT Analysis |
8.9. | Extrusion: Pneumatic |
8.10. | Extrusion: Mechanical |
8.11. | Extrusion: Companies |
8.12. | Extrusion: Example |
8.13. | Extrusion: SWOT Analysis |
8.14. | LIFT: Laser-Induced Forward Transfer |
8.15. | LIFT: Companies |
8.16. | LIFT: SWOT Analysis |
8.17. | Microvalve: Solenoid |
8.18. | Microvalve: Companies |
8.19. | Microvalve: SWOT Analysis |
8.20. | Industry-wide Technical Challenges |
8.21. | The Ideal 3D Bioprinter |
8.22. | Animal Studies |
8.23. | Future Technological Directions |
9. | SCAFFOLD TECHNOLOGIES |
9.1. | Tissue Engineering Scaffolds |
9.2. | Ideal Scaffold |
10. | 3D PRINTING |
10.1. | Introduction |
10.2. | Examples of 3D Printed Medical Products |
10.3. | Thermoplastic Extrusion |
10.4. | Thermoplastic Extrusion: Example |
10.5. | Thermoplastic Extrusion: Key Manufacturers |
10.6. | Thermoplastic Extrusion: SWOT Analysis |
10.7. | Material Jetting |
10.8. | Material Jetting: Key Players |
10.9. | Material Jetting: SWOT Analysis |
10.10. | Stereolithography |
10.11. | Stereolithography: Key Players |
10.12. | Stereolithography: SWOT Analysis |
10.13. | Stereolithography: Microstereolithography |
10.14. | Stereolithography: Projection |
10.15. | Stereolithography: Multiphoton Lithography |
10.16. | Stereolithography: Multiphoton Lithography: Example |
10.17. | Selective Laser Sintering |
10.18. | Selective Laser Sintering: Key Players |
10.19. | Selective Laser Sintering: SWOT Analysis |
11. | DECELLULARIZED ORGANS |
11.1. | Introduction |
11.2. | History |
11.3. | Decellularization |
11.4. | Recellularization |
11.5. | Companies |
11.6. | Future Technological Directions |
11.7. | Bioreactors |
12. | OTHER SCAFFOLD TECHNOLOGIES |
12.1. | Introduction |
12.2. | Phase Separation |
12.3. | Freeze-Drying |
12.4. | Freeze-Drying: Companies |
12.5. | Solvent Casting and Particle Leaching |
12.6. | Gas Foaming |
12.7. | Chemical Processes: Strengths and Weaknesses |
12.8. | Textile Technologies |
12.9. | Electrospinning |
12.10. | Cell Electrospinning |
12.11. | Electrospinning: Examples |
12.12. | Electrospinning: SWOT Analysis |
12.13. | Melt Electrospinning |
12.14. | Melt Electrospinning: SWOT Analysis |
12.15. | Electrospinning: Companies |
13. | SCAFFOLDLESS TECHNOLOGIES |
13.1. | Introduction |
13.2. | Cell Spheroids |
13.3. | Cell Spheroids: Self-Assembly |
13.4. | Cell Spheroids: Self-Organization |
13.5. | Cell Spheroids: Rotational Culture Equipment |
13.6. | Cell Spheroids: Key Companies |
13.7. | Cell Sheets |
13.8. | Cell Therapy Devices |
13.9. | Cell Therapy Devices: Companies |
14. | TISSUE ENGINEERING CHALLENGES |
14.1. | Industry-Wide Technical Challenges |
14.2. | Biopreservation |
14.3. | Vascularization |
15. | COMPANY PROFILES |
15.1. | 3D Bioprinting Solutions/ Vivax Bio |
15.2. | 3D Biotek |
15.3. | 3Dynamic Systems Ltd |
15.4. | Aether Inc. |
15.5. | Aspect Biosystems |
15.6. | ATERA |
15.7. | Avery Therapeutics |
15.8. | AxoSim |
15.9. | BioBots |
15.10. | BioDan Group |
15.11. | BIOLIFE4D |
15.12. | Cellenion SASU |
15.13. | Cellf BIO |
15.14. | Cellink |
15.15. | CUTISS |
15.16. | Digilab Inc. |
15.17. | GeSiM |
15.18. | Hesperos |
15.19. | Histogenics |
15.20. | Lena Biosciences |
15.21. | Microdrop Technologies GmbH |
15.22. | MicroFab Technologies |
15.23. | Mimetas |
15.24. | PeptiGel Design Ltd |
15.25. | Poietis |
15.26. | Prellis Biologics |
15.27. | Regemat 3D |
15.28. | RegenHU |
15.29. | SE3D |
15.30. | Sichuan Revotek Co. Ltd. |
15.31. | Synthecon |
15.32. | Tara Biosystems |
15.33. | TissUse |
15.34. | Upside Biotechnologies |
Slides | 279 |
---|---|
Companies | 34 |
Forecasts to | 2028 |